Corcept Therapeutics Incorporated
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +4.6% | +5.5% | +8.9% | +9.8% | +7.2% | +0.7% | -5.3% | +2.7% | +1.6% | -2.6% | +9.1% | |
| – | +6.3% | +9.8% | +11.4% | -16.7% | +1.0% | -7.0% | +1.1% | +22.1% | -10.3% | -12.2% | +3.2% | |
| – | +21.2% | +10.5% | -14.1% | +6.8% | -7.0% | -29.6% | +14.4% | +21.8% | -3.7% | -9.8% | +2.1% | |
| – | +3.7% | +11.6% | +15.2% | -19.6% | +0.8% | -15.8% | +6.0% | +23.2% | -11.7% | -9.1% | -8.9% | |
| – | +13.8% | +11.8% | -11.6% | +11.5% | -7.3% | +45.4% | -18.7% | +7.1% | -18.7% | -34.6% | +96.9% | |
| – | +2.9% | -7.0% | +16.1% | -3.6% | +54.2% | +15.8% | -14.6% | +0.6% | +4.2% | +0.2% | +2.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -13.2% | -5.9% | +9.5% | +22.9% | +10.7% | +1.4% | +1.7% | +15.5% | -1.5% | -6.3% | +3.4% | |
| – | -14.3% | -7.0% | +3.7% | +25.3% | +11.5% | +1.6% | +1.1% | +19.1% | -3.6% | -10.2% | +3.1% | |
| – | -32.9% | -49.7% | -42.1% | +881.8% | +91.9% | +18.7% | +3.4% | +3.2% | +3.2% | +50.1% | +17.8% | |
| – | +4.1% | -27.8% | +55.2% | -4.6% | -17.3% | +81.8% | -15.8% | +46.4% | +17.4% | -17.6% | -55.2% | |
| – | +9.8% | +8.1% | +8.8% | +7.1% | +6.4% | +0.5% | -7.0% | -0.6% | +2.5% | -1.5% | +10.6% | |
| – | +8.4% | +6.9% | +8.2% | +10.1% | +6.0% | +3.8% | +6.2% | +3.3% | +3.9% | -4.9% | +7.0% | |
| – | -0.2% | -0.9% | +1.2% | +2.2% | +4.2% | +1.1% | +0.6% | -0.9% | +0.3% | -12.9% | +13.4% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.